Asociación de Pembrolizumab con la respuesta tumoral y la supervivencia en pacientes con melanoma avanzado

Ribas et al. (martes,) estudiaron esta cuestión.

www.synapsesocial.com/papers/69dd67af7808b00a4799da19 — DOI: https://doi.org/10.1001/jama.2016.4059

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial· 2014 · 1,759 citations
2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,261 citations
3. THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL· 1934 · 4,710 citations
4. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).· 2014 · 25 citations
5. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab· 2023 · 230 citations